Altmetrics
Downloads
119
Views
53
Comments
0
This version is not peer-reviewed
Submitted:
19 June 2024
Posted:
20 June 2024
You are already at the latest version
Particle and Size | Test on microbial strains | Concentration | Mechanism of action | Ref |
---|---|---|---|---|
Silver nanoparticles (7 nm) |
E. coli (Gram-negative) S. aureus(Gram-positive) |
3.38 and 6.75 μg/mL | Damage DNA and disturb the synthesis of protein | [36] |
Silver oxide nanoparticles (42.7 nm) |
Streptococcus mutans (Gram-positive) Lactobacillus acidophilus (Gram-positive) |
Streptococcus mutans: At conc 250 μg zone of inhibition (ZI) was 6 ± 0.8 mm, MBC was 22 ± 0.2% L. acidophilus: zone of inhibition 8 ± 0.4 mm, MBC 25 ± 0.5% |
Mechanism unclear | [37] |
Fluorescent Ag nanoparticles (nAg-Fs), 1.5 nm |
Staphylococcus epidermidis NCIM2493, Bacillus megaterium (Gram-positive) Pseudomonas aeruginosa ATCC27853, Escherichia coli (Gram-negative) |
No cell growth was observed at conc. 2.0 μg/mL | Penetration of nAg-NPS into cell cytoplasm, leakage of cytoplasmic contents | [38] |
SDS-stabilized silver nanoparticles (AgNPs), 25 nm |
Candida albicans (I, II) Candida tropicalis, Candida parapsilosis |
0.052 mg/L (C. albicans I) 0.1 mg/L (C. albicans II) 0.42 mg/L (C. tropicalis) 0.84 mg/L (C. parapsilosis) |
The surfactant activity of NPs disrupts the cell wall of yeast. | [39] |
Silver nanoparticles (30–50 nm) | HIV-1 isolates | 0.44 to 0/91 mg/mL | Prevention of CD-4 dependent virion binding, fusion, infectivity, inhibition of post-entry stages of HIV-1 lifecycle. | [40] |
Silver/chitosan nanoparticles (3.5, 6.5, 12.9 nm) | H1N1 influenza A | 100 μg of Ag NPs was added to 1 mg of chitosan | Inhibiting viral penetration into the host cell | [41] |
Silver nanoparticles of Lampranthus coccineus (10.12–27.89 nm), Malephora lutea (8.91–14.48 nm). | HAV-10, HSV-1, CoxB4 |
L. coccineus: HAV-10- no activity, HSV-1- 520.6μg/mL, COxB4- no activity (aqueous nano extract) 11.7μg/mL, 36.36μg/mL, 12.74μg/mL (hexane nano extract) M. lutea: no activity for aqueous nano extract, HAV-10- 31.38μg/mL, HSV-1-no activity, COxB4- 29.04μg/mL (hexane nano extract) |
Not determined | [42] |
Copper nanoparticles (3–10 nm) |
Phoma destructiva (DBT 66) Curvularia lunata (MTCC, 2030) Alternaria alternate (MTCC 6572) Fusarium oxysporum (MTCC 1755) |
Zone of inhibition (ZI) value for Phoma destructive: 22 ± 1 mm Curvularia lunata: 21 ± 0.5 mm Alternaria alternate: 18 ± 1 mm Fusarium oxysporum: 24 ± 0.5 mm |
Not clearly mentioned | [43] |
Cuprous oxide nanoparticles (45.4 ± 68 nm) | Hepatitis C virus (HCV) | 2 μg/mL | Attachment and entry Inhibition of HCV infection | [44] |
Copper Iodide nanoparticles (160 nm) | Feline Calicivirus | 10 ng/mL to 10 μg/mL | ROS generation and subsequent capsid protein oxidation | [45] |
Gold-chitosan hybrid nanoparticles (16.9 nm) |
S. aureus (Gram positive) P. aeruginosa (Gram-negative) |
0.25 mg/mL | Mechanism still unclear | [46] |
Gold nanoparticles (25 nm) | Candida sp | 16–32 μg/mL | Inhibition of H + ATPase leads to intracellular acidification and cell death | [47] |
Gold nanoparticles (17 nm) | HIV-1 | 0.05–0.12 mg/mL | The mechanism of gold nanoparticles against HIV-1 is not clear but it inhibits the HIV-1 fusion | [48] |
Zinc oxide nanoparticles (30 nm) | Camphylobacter jejuni (Gram-negative) | 0.05–0.025 mg/mL | Disruption of the cell membrane and oxidative stress in C. jejuni. | [49] |
Zinc oxide nanoparticles (70 nm) |
Botrytis cinerea Penicillium expansum |
3–12 mol/Ll−1 | Inhibition of growth by affecting cellular functions | [50] |
Zinc oxide nanoparticles (ZnO NPs), 70 ± 15 nm |
Botrytis cinerea, Penicillium expansum |
3 mmol/L | Deformation in fungal hyphae by affecting cellular function | [50] |
Zinc oxide nanoparticles (12–32 nm) |
Alternaria alternata (ITCC 6531), Aspergillus niger (ITCC 7122), Botrytis cinerea (ITCC 6192), Fusarium oxysporum (ITCC 55), Penicillium expansum (ITCC 6755) |
64 μg/mL (A. alternata) 16 μg/mL (A. niger) 128 μg/mL (B. cinerea) 64 μg/mL (F. oxysporum) 128 μg/mL (P. expansum) |
Disruption of membrane structure and change in permeability. | [51] |
Zinc oxide nanoparticles (16–20 nm) | H1N1 Influenza | 75 and 200 μg/mL | Suppress the proliferation of influenza virus at an inhibition rate of 52.2% | [52] |
Zero-valent Iron (Fe°) nanoparticles, spherical (31.1 nm) |
Staphylococcus aureus (Gram-positive) E. coli (Gram-negative) |
MIC for both strains at 30 μg/mL and complete growth inhibition at 60 μg/mL | Oxidative stress generation via ROS and visible damage to bacterial protein and DNA. | [53] |
Magnetic Iron oxide nanoparticles (50–110 nm) | S. aureus (Gram-positive) | DMF solution with 40 and 60 mJ laser fluencies showed the highest antibacterial activity | This could be due to stress generated by ROS disrupting the bacterial cell membrane. | [54] |
Iron oxide nanoparticles (10–30 nm) | Trichothecium roseum, Cladosporium herbarum, Penicillium chrysogenum, Alternaria alternate and Aspergillus niger. | Varies between 0.063-0.016 mg/mL | Formation of ROS, damage of protein, and DNA by oxidative stress. | [55] |
Nickel ferrite (NiFe2O4) nanoparticles (NFOTP) | Staphylococcus aureus NCIM 5021, Streptococcus pyogenes NCIM 5280 (Gram-positive) Escherichia coli NCIM 2345, Salmonella typhimurium NCIM 2501 (Gram-negative) |
Zone of inhibition for E. coli was seen but no numeric value is mentioned. | Higher negatively charged surface of E. coli, thin surface and formation of reactive oxidative species (ROS) and oxidative stress lead to cell death. | [56] |
Iron oxide nanoparticles (10–15 nm) | A/Puerto Pico/8/1934H1N1 influenza virus strain (PR8-H1N1) | 1.1 pg | Inactivation of cell protein through the interaction of nanoparticles and –SH group (Proposed, not investigated yet) | [56] |
TiO2 nanoparticles (70–100 nm) | Candida albicans | 5.14 μg/mL | Inhibition of fungal biofilms | [57] |
BaSO4 nanoparticles (73 nm) |
Staphylococcus aureus; P. aeruginosa (Schroeter) ;Migula |
Nano BaSO4, 40% | Hypothesized the difficulty of preliminary steps on bacterial adhesion due to the nano roughness of the material | [58] |
Nanomaterial | Functionalization | Cell Lines | Ref |
Graphene-based nanosheets | Surface functionalization by bio-compatible targeting ligands and coatings | MDA-MB-468 (MCF-7) | [75] |
Molybdenum disulfide nanosheets | Chitosan; PLGA, PEG functionalization | Breast cancer cells (MDA-MB-468), HeLa uterine cancer cells, human lung cancer cells | [76] |
Transition metal nanoparticles decorated with polymers | Polymer functionalization | Mice bearing 4T1 breast cancer cell xenografts | [77] |
Lanthanide-activated nanoparticles | Doping with lanthanide | Cancer cells xenografted in mice | [78] |
Group IV quantum dots | Surface functionalization | Various cancer cell types | [79] |
Graphene oxide nanosheets | Surface functionalization | Tumor cells | [80] |
Peptide-based nanoparticles | Chemical functionalization | Peptide-treated HeLa cells preloaded with Hg2+ | [81] |
Silver nanoparticles | Aptamer conjugation | Leukemia cells, neural stem cells, kidney tissue, renal carcinoma cells | [82] |
Gold nanoprisms | Conjugation with polyethylene glycol | Gastrointestinal carcinoma cells (HT 29) | [83] |
Gold nanorods | Encasing by mesoporous silica | Carcinoma cells | [84] |
Magnetofluroscentnanoprobe | Surface functionalization | Human Breast Cancer (MCF-7), HeLa cells | [85] |
Dye-loaded nanoemulsions | Lipids conjugation with polyethylene glycol | Human colon cancer (HCT116), HeLa cells | [86] |
Cadmium telluride quantum dots | Capping by shells | Human bronchial epithelial cells | [87] |
Contrast agent | Blending method | Polymer | Application | Content | Reported effects | Polymer biodegradable | Biological response | Ref |
---|---|---|---|---|---|---|---|---|
BaSO4 | Blended in the powder phase | PMMA | Bone cement | 9–15 wt % | Hard particles, third body wear, reduced tensile and flexural strength | NO | Osteoclast formation | [88] [89] [90] |
Blended in the powder phase | PMMA | Vertebroplasty cement | 30 wt % | Hard particles, third body wear, lower viscosity | NO | Osteoclast formation | [91] [92] [93] |
|
Twin-screw micro-compounding | PLLA | Bioresorbable stents | 5–20 wt % | Increased tensile modulus and strength, decreased elongation at break and ductility | YES | No adverse effects after 21 days | [94] [95] |
|
Magnetic stirring in organic solvent | PLGA | Bioresorbable stent | 17.9 v/v % | Increased Young’s modulus, reduced elasticity, increased radial strength | YES | Na | [96] | |
Solution mixing | PLGA | Bone fixation plate | 1:10 and 1:3 w/w PLGA:BaSO4 | Radiopaque up to 56 days, BaSO4 leaching < 0.5 mg/day; insufficient to induce cytotoxicity | YES | No adverse effects | [97] | |
Lipiodol ultra fluid | Immersion in oil at elevated temperature | UHMWPE | TKA insert | 25 mL | Physical alteration–swelling, 54% reduction in surface radiopacity after 4 weeks | NO | Na | [98] |
Iohexol(IHX) | Stirring | PLA | Bioresorbable implants | 40 wt % | Reduced tensile strength, elongation at break and increased tensile modulus, enhanced crystallinity, slower polymer degradation | YES | Thin fiber capsule | [99] |
Blended in the powder phase | PMMA | Bone cement | 10 wt % | Better biocompatibility compared to conventional contrast agents | NO | Osteoclast formation | [90] | |
Iodixanol(IDX) | Blended in the powder phase | PMMA | Bone cement | 10 wt % | Higher osteoclast formation than IHX | NO | Osteoclast formation | [90] |
Iobitridol | Dissolved in liquid phase | CPC | Bone cement | 56 mg Ml^–1 | Rapid release of contrast, no significant change in mechanical properties, no effect on injectability, cohesion, or setting time | YES | No adverse effects | [100] |
Iodinated diphenol | Polymerization reaction | PLA diol | Coronary stent | <1% of 1 mL of iodine contrast | Increased ultimate tensile strength and elongation at break, long-term radiopacity | YES | No adverse effects | [101] |
Bismuth salicylate(BS) | Dissolved in liquid phase | PMMA | Vertebroplasty cement | 10 w/w | Reduced compressive and tensile strength, reduced strain, lower setting temperature, increased radiopacity, longer injection time, Better compatibility than BaSO4 | NO | Na | [102] [103] |
Triphenyl bismuth(TPB) | Dissolved in liquid phase | PMMA | Bone cement | 10 wt % | Increased ultimate tensile strength, Young’s modulus and strain to failure, lower setting temperature, better homogeneity | NO | Na | [104] |
Bismuth oxide Bi2O3 | Blended into fiber | UHMWPE | Sublaminar cables | 20 wt % | Decreased tensile strength, limited leaching below toxic levels | NO | No adverse effects | [105] [106] |
Titanium dioxide TiO2 | Blending | PE | Orbital implant | 6% | Slight decrease in tensile strength and modulus, significant decrease in compressive strength and modulus, reduced hardness | NO | No adverse effects | [107] |
Iron oxide Fe3O4 | Twin-screw extrusion | PLLA | Bone screws | 20 wt % | Reduced flexural strength, increased crystallinity, increased thermal stability | YES | Osteogenic effect, no adverse effects | [108] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated